SCHEMBL1123030

SCHEMBL1123030

C[C@H]1CC(=O)c2ccsc2S1(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.35
POLB P06746 1/20 0.35
HTR2C P28335 2/20 0.32
CES1 P23141 1/20 0.31
ALDH1A1 P00352 3/20 0.31
MAPT P10636 2/20 0.31
LMNA P02545 1/20 0.31
GFER P55789 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1122615 1.00 GAA (0.35) GAAPOLBHTR2CCES1ALDH1A1
SCHEMBL3350738 1.00 GAA (0.35) GAAPOLBHTR2CCES1ALDH1A1
SCHEMBL9422808 0.75 POLB (0.36) GAAPOLB
SCHEMBL8792481 0.71 KDM4E (0.38) GAAPOLBALDH1A1MAPTLMNA
SCHEMBL16886968 0.67 HTR2C (0.39) HTR2CCES1ALDH1A1MAPTLMNA
SCHEMBL15606100 0.67 HTR2C (0.39) HTR2CCES1ALDH1A1MAPTLMNA
SCHEMBL13852722 0.67 DRD2 (0.33) GAAPOLB
SCHEMBL16892359 0.66 CA2 (0.43) LMNA
SCHEMBL15384943 0.66 CA2 (0.56) LMNA
SCHEMBL2307894 0.66 GAA (0.55) GAAPOLBHTR2CCES1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0590549-B1 Process for preparing thienothiopyran derivative KANEGAFUCHI CHEMICAL IND (JP) 1998-07-15 EP claimed
US-5565345-A REDUCTION BY THE ACTION OF A MICROORGANISM KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-10-15 US claimed
EP-0590549-A1 Process for preparing thienothiopyran derivative KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-04-06 EP claimed
JP-6107667-A None JP disclosed
US-9481686-B2 Process for preparing enantiomerically enriched oxamides ZACH SYSTEM S.P.A. (IT) 2016-11-01 US disclosed
US-20150191485-A1 Process for Preparing Enantiomerically Enriched Oxamides F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2015-07-09 US disclosed
EP-2683724-B1 ASYMMETRIC REDUCTION PROCESS ZACH SYSTEM SPA (IT) 2015-05-06 EP disclosed
EP-2683724-B1 ASYMMETRIC REDUCTION PROCESS ZACH SYSTEM SPA (IT) 2015-05-06 EP disclosed
US-8927740-B2 Asymmetric reduction process ZACH SYSTEM S.P.A. (IT) 2015-01-06 US disclosed
US-8927740-B2 Asymmetric reduction process ZACH SYSTEM S.P.A. (IT) 2015-01-06 US disclosed
EP-2683724-A1 ASYMMETRIC REDUCTION PROCESS ZaCh System S.p.A. (IT) 2014-01-15 EP disclosed
EP-1828198-A4 METHOD FOR SEPARATING OF OPTICALLY PURE THIOPHENE COMPOUNDS USING SIMULATED MOVING BED CHROMATOGRAPHY SK HOLDINGS CO LTD (KR) 2008-12-03 EP disclosed
EP-1828198-A1 METHOD FOR SEPARATING OF OPTICALLY PURE THIOPHENE COMPOUNDS USING SIMULATED MOVING BED CHROMATOGRAPHY SK Corporation (KR) 2007-09-05 EP disclosed
WO-2006068333-A1 METHOD FOR SEPARATING OF OPTICALLY PURE THIOPHENE COMPOUNDS USING SIMULATED MOVING BED CHROMATOGRAPHY SK CORPORATION (KR) 2006-06-29 WO disclosed
EP-0590549-B1 Process for preparing thienothiopyran derivative KANEGAFUCHI CHEMICAL IND (JP) 1998-07-15 EP disclosed
US-5565345-A REDUCTION BY THE ACTION OF A MICROORGANISM KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-10-15 US disclosed
US-5565345-A REDUCTION BY THE ACTION OF A MICROORGANISM KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-10-15 US disclosed
JP-H06107667-A PRODUCTION OF THIENOTHIOPYRAN DERIVATIVE KANEGAFUCHI CHEM IND CO LTD 1994-04-19 JP disclosed
EP-0590549-A1 Process for preparing thienothiopyran derivative KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-04-06 EP disclosed
EP-0590549-A1 Process for preparing thienothiopyran derivative KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1994-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191485-A1 Process for Preparing Enantiomerically Enriched Oxamides OTC, CYP11B2, QDPR GAA 646/4885POLB 996/4885HTR2C 2873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.